冬凌草甲素长循环固体脂质纳米粒的制备及对人胃癌SGC—7901细胞的抑制作用(3)
![]() |
第1页 |
参见附件。
[参考文献]
[1] Liu Z,Ouyang L,Peng H,et al. Oridonin:targeting programmed cell death pathways as an anti-tumour agent [J]. Cell Prolif,2012,45(6):499-507.
[2] Chen JH,Wang SB,Chen DY,et al. The inhibitory effect of oridonin on the growth of fifteen human cancer cell lines [J]. Chin J Clni Oncol,2007, 4(1):403-406.
[3] Ikezoe T,Chen SS,Tong XJ,et al. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells [J]. Int J Oncol,2003,23(4):1187-1193.
[4] 徐文,孙进,张婷婷,等.HPLC法测定冬凌草甲素的平衡溶解度和表观油水分配系数[J].沈阳药科大学学报,2007,24(4):220-222.
[5] Zhang WJ,Huang QL,Hua ZC,et al. Oridonin:A promising anticancer drug from China [J]. Frontiers in Biology,2010,5(6):540-545.
[6] 陈美婉,陈锐娥,李颖博.冬凌草甲素纳米制剂的研究和应用[J].中国实验方剂学杂志,2011,17(16):284-287.
[7] 肖琴,陈芳,常明泉,等.槲皮素固体脂质纳米粒体外释放度考察[J].中国医药导报,2012,9(25):135-137.
[8] Xu J,Zhao JH,Liu Y,et al. RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin [J]. Int J Nanomedi cine,2012,7:211-9.
[9] 王炯,周小菊,胡先明.甘草次酸长循环固体脂质纳米粒的制备与体外性能研究[J].中国药房,2012,23(15):1364-67.
[10] Zheng D,Dai W,Zhang D,et al. In vivo studies on the oridonin-loaded nanostructured lipid carriers [J]. Drug Deliv,2012,19(6):286-291.
[11] 赵永星,华海婴,梁文权.冬凌草甲素纳米粒备及其体外抗肿瘤作用[J].中国医院药学杂志,2008,28(11):864-867.
[12] 邢贞建,李祥,陶涛.青蒿琥酯纳米粒的制备及其体外细胞抑制试验[J].中国药房,2011,22(25):2357-2360.
[13] Washington C. Evaluation of non-sink dialysis methods for the measu rement of drug release from colloids:effect of drug partition [J]. Int J Pharm,1989,56:71.
(收稿日期:2013-03-05 本文编辑:程 铭)
您现在查看是摘要介绍页,详见PDF附件。